SH2B1在非小细胞肺癌中的表达水平及与临床病理参数和预后的关系

Expression of SH2B1 in non-small cell lung cancer and its relationships with clinicopathological parameters and prognosis

目的观察SH2B衔接因子蛋白1(SH2B1)在非小细胞肺癌组织中表达情况,并探讨SH2B1与临床病理特征及预后的关系。方法选取2013年9月-2015年6月在青海省第五人民医院进行手术治疗的51例非小细胞肺癌患者的癌组织标本为非小细胞肺癌组织组,另选取距癌组织边缘≥5 cm的癌旁组织作为癌旁组织组。分别采用荧光实时定量聚合酶链反应法(qRT-PCR)与免疫印迹法(Western blot)检测SH2B1 mRNA、SH2B1蛋白相对表达情况;应用免疫组织化学法(SP)检测SH2B1蛋白表达;分析SH2B1与临床病理参数的关系,采用Kaplan-Meier对非小细胞肺癌患者3年生存情况进行分析;并对影响非小细胞肺癌预后的因素进行COX回归分析。结果与癌旁组织相比,非小细胞肺癌组织中SH2B1 mRNA、SH2B1蛋白表达水平显著升高(P<0.05),SH2B1蛋白阳性率显著高于癌旁组织(62.7%vs.31.4%)(P<0.05)。SH2B1在有淋巴结转移、分化程度低、TNM分期为Ⅲ~Ⅳ期患者癌组织中表达量高于无淋巴结转移、分化程度中高、TNM分期为Ⅰ~Ⅱ期患者(P<0.05)。Kaplan-Meier分析结果显示SH2B1高表达组三年内存活率低于SH2B1低表达组(18.8%vs.63.2%)(P<0.05);多因素COX回归分析结果显示SH2B1阳性表达是影响非小细胞癌不良预后的独立危险因素。结论SH2B1基因在非小细胞肺癌组织中高表达,其异常表达与患者临床病理指标及预后不良密切相关,推测SH2B1可能参与非小细胞肺癌的癌变过程。

Objective To observe the expression of SH2B binding factor 1(SH2B1)in non-small cell lung cancer(NSCLC)tissues and explore the relationships between SH2B1 with clinicopathological features and prognosis.Methods Cancer tissue specimens from 51 patients with non-small cell lung cancer who underwent surgical treatment in our hospital from September 2013 to June 2015 were selected as non-small cell lung cancer tissue group,the adjacent tissues≥5 cm from the margin of the cancer tissues were selected as the adjacent tissue group;the relative expressions of SH2B1 mRNA and SH2B1 protein were detected by fluorescence real-time quantitative polymerase chain reaction(qRT-PCR)and Western blot,respectively;the expression of SH2 B1 protein was detected by immunohistochemistry(SP);the relationship between SH2B1 and clinicopathological parameters was analyzed.Kaplan-Meier was used to analyze the 3-year survival of patients with non-small cell lung cancer;the prognostic factors of NSCLC were analyzed by COX regression.Results Compared with the adjacent tissues,SH2B1 mRNA and SH2B1 protein expression levels in NSCLC group were significantly increased(P<0.05);the positive rate of SH2B1 protein in cancer tissues was significantly higher than that in adjacent tissues(62.7%vs.31.4%)(P<0.05);the expression levels of SH2B1 in cancer tissues of patients with lymph node metastasis,low differentiation,and TNM stage III-IV were higher than those of patients without lymph node metastasis,with medium to high degree of differentiation and TNM stageⅠ-Ⅱ(P<0.05).Kaplan-Meier analysis showed that the three-year survival rate of SH2B1 high expression group was lower than that of SH2B1 low expression group(18.8%vs.63.2%)(P<0.05);multivariate COX regression analysis showed that SH2B1 positive expression was an independent risk factor for poor prognosis of non-small cell carcinoma.Conclusion SH2B1 gene was highly expressed in non-small cell lung cancer tissues;its abnormal expression was closely related to the clinicopathological indexes and poor prognosis of patients.It is speculated that SH2B1 might be involved in the carcinogenesis of non-small cell lung cancer.